Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?

@article{Caporali2014ModulatingTC,
  title={Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?},
  author={Roberto Caporali and Serena Bugatti and Lorenzo Cavagna and Marco Antivalle and Piercarlo Sarzi-Puttini},
  journal={Autoimmunity reviews},
  year={2014},
  volume={13 1},
  pages={49-53}
}
Advances in our understanding of the key mediators of chronic inflammation and tissue damage in rheumatoid arthritis (RA) have fostered the development of targeted therapies and greatly expanded the available treatment options. Abatacept, a soluble human fusion protein that selectively modulates the co-stimulatory signal required for full T-cell activation, is approved for the treatment of moderate to severe RA in the United States, Canada, and the European Union. This review summarises the… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Autoimmunity in 2014.

Clinical reviews in allergy & immunology • 2015
View 1 Excerpt

Co-stimulation Therapy in Rheumatoid Arthritis: Today and Tomorrow

Current treatment options in rheumatology • 2015
View 1 Excerpt

Leukocyte-specific protein 1 regulates T-cell migration in rheumatoid arthritis.

Proceedings of the National Academy of Sciences of the United States of America • 2015

References

Publications referenced by this paper.
Showing 1-10 of 48 references

Similar Papers

Loading similar papers…